Why the Immutep (ASX:IMM) share price will be in focus today

The Immutep (ASX: IMM) share price will be on watch this morning follwing an update on the company's patent application. Here are the details.

| More on:

Should you invest $1,000 in Pilbara Minerals Limited right now?

Before you buy Pilbara Minerals Limited shares, consider this:

Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now... and Pilbara Minerals Limited wasn't one of them.

The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

And right now, Scott thinks there are 5 stocks that may be better buys...

See The 5 Stocks *Returns as of 30 April 2025

asx share price on watch represented by investor looking through magnifying glass

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Immutep Ltd (ASX: IMM) shares will be on watch this morning after the company announced it has secured a second United States patent for eftilagimod alpha. The Immutep share price ended Tuesday's trading session up 8.1% to 33 cents.

Immutep is a global biotech that is focused on developing immunotherapy therapies for cancer and autoimmune diseases. Its lead product, eftilagimod alpha, is a soluble LAG-3Ig fusion protein based on the LAG-3 which is in clinical development.

New patent added

The Immutep share price could be on the move today following the company's latest update released after yesterday's market close 

According to its release, Immutep has been granted patent number 10,940,181 by the United States Patent & Trade Mark Office. The new patent is titled, 'Combined Preparations for the Treatment of Cancer or Infection'.

This follows a previous patent that was announced by the company on 30 December 2020.

The new patent builds another layer to the protection of Immutep's intellectual property. In particular, it relates to methods of treating cancer by administering the company's lead drug candidate, eftilagimod alpha, in combination with a PD-1 pathway inhibitor.

The expiry of the additional patent falls on 20 January 2036.

In other news that could impact the Immutep share price today, the company noted it has filed another divisional application to expand on other related aspects of its invention.

Words from the head of Immutep

Immutep CEO Marc Voigt hailed the company's progress in securing the new patent. He said:

We are very pleased to add another United States patent to our expanding patent portfolio, especially in this case, because of its direct relevance to our clinical development programs. These patent grants are important as they underpin ongoing investment in clinical development of efti and allow us to confidently engage in business development discussions.

Immutep share price review

The Immutep share price is down just over 4% when looking at its chart over the past 12 months. Immutep shares dropped steeply last March from 30 cents to an all-time low of 10 cents. While its shares slowly recovered over the remainder of 2020, they spiked in December from the results of the company's breast cancer trial.

Since then, profit taking and weak market sentiment have steadily led Immutep shares lower. 

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Market News

Man standing on rock next to turquoise salt lagoon.
Share Gainers

Here are the top 10 ASX 200 shares today

The ASX 200 finally had a green session this hump day.

Read more »

gaming asx share price rise represented by slot machine paying jackpot
Broker Notes

What does Macquarie expect from Aristocrat Leisure shares when it reports on 14 May?

Here's what the broker is expecting from this gaming technology company next week.

Read more »

Man pointing at a blue rising share price graph.
Share Gainers

Guess which ASX 300 stock just rocketed 17%!

Investors are sending the ASX 300 stock soaring higher on Wednesday. But why?

Read more »

Broker written in white with a man drawing a yellow underline.
Broker Notes

Top brokers name 3 ASX shares to buy today

Here's what brokers are recommending as buys this week.

Read more »

A male investor wearing a blue shirt looks off to the side with a miffed look on his face as the share price declines.
Share Fallers

Why Aurizon, JB Hi-FI, Nuix, and Platinum shares are tumbling today

These shares are falling on hump day. But why?

Read more »

A young woman wearing overalls and a yellow t-shirt kicks one leg in the air showing excitement over the latest ASX 200 shares to hit 52-week highs
Share Gainers

Why Firefly, Kelsian, NAB, and Zip shares are roaring higher today

These shares are having a good time on hump day. Let's find out why.

Read more »

A man and woman sit at a desk staring intently at a laptop screen with papers next to them.
Opinions

Where I'd invest $5,000 in ASX 300 shares right now

These stocks look like excellent investments today.

Read more »

A man holding a cup of coffee puts his thumb up and smiles while at laptop.
Broker Notes

Goldman Sachs says these ASX 200 stocks are strong buys

The broker is feeling very bullish about these stocks. But why?

Read more »